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Abstract
Background: Bcl-2 and Bcl-XL are anti-apoptotic paralogues that inhibit apoptosis elicited by a
wide variety of stimuli, and play critical roles in cancer development and resistance to treatment.
Many clinical studies have indicated that expression of these anti-apoptotic proteins in tumours is
associated with poor prognosis. It has therefore been assumed that in cells the essential difference
between Bcl-2 and Bcl-XL involves regulation of expression and that they are otherwise
functionally similar. To examine this issue, we have compared the function of the proteins and of
mutants of Bcl-2 and Bcl-XL specifically targeted to different subcellular sites.
Methods: We generated clones of the human breast cancer line MCF-7 stably expressing known
amounts of Bcl-2, or Bcl-XL as determined by quantitative immunoblotting. Clones expressing
equivalent amounts of wild-type and mutants of Bcl-2 and Bcl-XL with subcellular localization
restricted to the cytoplasm, endoplasmic reticulum or outer mitochondrial membrane were
studied in both MCF-7 and Rat-1 fibroblasts. In MCF-7 cells we measured the functional activities
of these proteins in preventing apoptosis induced by four different agents (doxorubicin, ceramide,
thapsigargin, TNF-α). Etoposide and low serum were used to compare the effect of Bcl-2, Bcl-XL
and mutants located at the endoplasmic reticulum on induction of apoptosis in fibroblasts.
Results: We noted both qualitative and quantitative differences in the functional activity of these
two anti-apoptotic proteins in cells: Bcl-2 localized to the endoplasmic reticulum inhibits apoptosis
induced by ceramide and thapsigargin but not by doxorubicin or TNFα, while Bcl-XL at the
endoplasmic reticulum is active against all four drugs. In fibroblasts Bcl-2 localized to the ER did not
prevent cell death due to etoposide whereas Bcl-XL in the same location did. Finally in MCF-7 cells,
Bcl-XL is approximately ten times more active than Bcl-2 in repressing apoptosis induced by
doxorubicin. This difference can be manifest as a large difference in clonal survival.
Conclusion: When examined in the same cellular context, Bcl-2 and Bcl-XL differ substantially in
the potency with which they inhibit apoptosis, mediated in part by differences in the inhibition of
specific subcellular pathways.
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Background
Apoptosis is a critical process that is dysregulated in
tumourigenesis [1]. Bcl-2 was the prototypic anti-apop-
totic protein, and Bcl-XL was the first protein discovered
with similar function [2]. Since then the Bcl-2 family has
expanded to include more than 6 anti-apoptotic and
many pro-apoptotic members [3]. Bcl-2 and Bcl-XL dis-
play 43 % amino acid identity, share regions of sequence
similarity [4,5] as well as a C-terminal hydrophobic
region required for membrane localization [2], and repre-
sent the most recent additions to the Bcl-2 family [6]. Bcl-
2 and Bcl-XL appear to function in the same apoptotic
pathway [7], and both confer resistance to multiple chem-
otherapy agents when tested in experimental systems.
Over-expression of either protein is usually associated
with poor prognosis in many human cancers (reviewed in
8). However, in some cancer types multiple anti-apoptotic
proteins are expressed [9], and have opposite effects on
prognosis [10-12] indicating that there may be subtle, but
clinically and biologically relevant functional differences
between family members. Experiments in mice with dele-
tion of individual anti-apoptotic genes indicate that the
phenotypes are not identical [13]. However, it is generally
accepted that this is due to expression in different tissues
or in the same tissue but at different times rather than
being a consequence of differences in the potency or
mechanism of action of the different anti-apoptotic pro-
teins.
The mechanisms of action of Bcl-2 and Bcl-XL are com-
plex, with many postulated interactions with other pro-
teins, and the role of any single interaction in the final
phenotype at the cellular level remains ill-defined. Bcl-2 is
located at the mitochondrion, endoplasmic reticulum
(ER) and the nuclear envelope [14,15]. Bcl-XL resides in
the nuclear envelope, extra-nuclear membranes, including
the mitochondrion but also cytosol [16,17]. Bcl-2 is tar-
geted to membranes by a carboxyl-terminal tail-anchor
[15], and by replacing the tail-anchor with heterologous
sequences specific for insertion into either ER or mito-
chondria, we have created fusion proteins targeted to indi-
vidual organelles [18]. These targeted mutants defined
distinct but overlapping Bcl-2 regulated apoptosis path-
ways at individual organelles [18-22]. Here we have cre-
ated similar mutants of Bcl-XL to compare organelle
specific inhibition of apoptosis by Bcl-2 and Bcl-XL.
The human breast cancer cell line MCF-7 transfected with
plasmids expressing either Bcl-2 or Bcl-XL is an excellent
system in which to examine the differences between these
two proteins as the cells do not express detectable Bcl-XL,
and endogenous Bcl-2 can be drastically reduced by
growth in estrogen depleted medium [23]. Therefore, the
background due to endogenous anti-apoptotic proteins is
minimal, and the effects of exogenously expressed pro-
teins can be monitored. As adherent cells, they can be
studied by immunofluorescence microscopy to determine
the location of organelle-targeted mutants. MCF-7 cells
lack caspase-3 due to a genomic deletion [24], potentially
decreasing feedback activation of other caspases, simplify-
ing the analysis of individual apoptotic pathways [25].
Finally, most human breast cancers originate in epithelial
cells that express Bcl-2 or Bcl-XL [26-28]. Clinical studies
have demonstrated that increased levels of Bcl-XL in
breast carcinoma are associated with a poor outcome [12].
Conversely and paradoxically, Bcl-2 expression confers a
better prognosis than lack of expression [10,11]. How-
ever, the association of Bcl-2 with expression of the estro-
gen receptor (a strong independent predictor of good
outcome) has confounded these studies.
To examine different apoptosis pathways in cells express-
ing Bcl-2, Bcl-XL or one of the targeted mutants, we exam-
ined the response of MCF-7 cells to several stimuli that
differentially engage organelle specific pathways of apop-
tosis [29,30]. To determine how general the qualitative
differences between Bcl-2 and Bcl-XL are we also assessed
the function of the wild-type proteins and targeted
mutants of Bcl-2 and Bcl-XL in a Rat-1 fibroblast cell line
used previously to demonstrate differences in the regula-
tion of apoptosis at ER and mitochondria [18,29,30].
Doxorubicin was selected to examine the differences
between the various cell clones quantitatively, as this drug
is used extensively in treating breast cancer patients and it
is well characterized as an apoptotic stimulus for MCF-7
cells [23]. Thus, quantitatively assaying doxorubicin-
induced apoptosis, both by monitoring the cleavage of
PARP and by assessing clonogenic survival in the estrogen
receptor positive MCF-7 line represents an excellent cellu-
lar context in which to measure and analyze differences
between Bcl-2 and Bcl-XL. Unexpectedly, our results dem-
onstrate that Bcl-2 and Bcl-XL differ substantially in the
potency with which they inhibit apoptosis, mediated in
part by differences in the inhibition of specific subcellular
pathways. These data suggest caution in interpreting
expression alone as directly proportional to functional
activity in clinical samples, and clearly show that Bcl-2
and Bcl-XL are functionally distinct.
Methods
Plasmids and recombinant proteins
Plasmids encoding targeted Bcl-2 mutants (Bcl2-acta and
Bcl2-cb5) have been previously described [18]. A similar
strategy was used for Bcl-XL: the cDNA encoding amino
acids 1 – 210 of Bcl-XL was fused either to the sequence
encoding the carboxyl-terminus of ActA or the cyto-
chrome b5 hydrophobic tail for mitochondrial or endo-
plasmic reticulum targeting, respectively. Bcl-XL lackingBMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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the carboxyl-terminal sequence was generated by insert-
ing a stop codon after nucleotide 630.
To purify Bcl-XL, DH5α cells were transformed with plas-
mid encoding a Bcl-XL-intein fusion protein. The fusion
protein was expressed and bound to a chitin column; after
washing the column, cleavage of the fusion protein was
induced with 30 mM DTT. Recombinant glutathione-S-
transferase (GST)-Bcl-2ΔTM [13] was purified on a glu-
tathione column.
Immunofluorescence
MCF-7 cells were analyzed by immunofluorescence as
previously described [18], using rabbit anti-Bcl-XL antis-
era followed by either a monoclonal antibody to the ER
protein calreticulin, or to an inner mitochondrial mem-
brane protein (2G2, ExAlpha Biologicals). Where indi-
cated, FITC was coupled directly to the primary antibody.
FITC and rhodamine donkey anti-rabbit and rhodamine
donkey anti-mouse were used as secondary antibodies.
Cells were analyzed using a Zeiss confocal microscope
and associated software (Carl Zeiss LSM510). To assess
apoptosis in rat fibroblasts the cells were stained with
Hoescht 33342 and Annexin V coupled to Alexa Fluor594
according to specifications of the manufacturer (Molecu-
lar Probes) and viewed by epifluorescence microscopy.
Cell culture
Stable transfectants of MCF-7 and Rat-1-MycERTAM
(referred to here as Rat-1) cell lines generated using
Geneporter (Gene Therapy Systems Inc) were analyzed for
expression by quantitative immunoblotting. Apoptosis
was induced in Rat-1 cells using etoposide or serum star-
vation as described previously [29,30]. To reduce expres-
sion of endogenous Bcl-2 in the MCF-7 cells the cells were
incubated in phenol red minus αMEM with 10 % charcoal
filtered FBS for 6 days prior to each experiment. MCF-7
cells were washed with PBS and incubated in the same
medium containing: doxorubicin (at the specified con-
centrations, for 24 hours), thapsigargin (400 nM, for 60
hours), ceramide (70 μM, for 20 hours), or TNFα and
cycloheximide (29 ng/ml and 10 ng/ml, respectively for
30 hours). Floating and adherent cells were harvested and
pelleted by centrifugation, the cell pellet washed twice in
PBS and resuspended in SDS lysis buffer (10 mM Tris-
HCl, pH 7.5; 10 mM NaCl; 1 % SDS and protease inhibi-
tors). An aliquot was removed for protein concentration
determination by BCA protein assay (Pierce), and the rest
of the cell lysate was diluted 1:1 with hot 4 % SDS, 0.1 M
Tris-HCl pH 8.9, 2 mM EDTA, 0.1 % bromophenol blue,
20 % glycerol and 0.25 M DTT, and stored at -80°C.
Quantitative immunoblotting
Cell lysates were processed as previously described [18].
The primary antibodies, source and dilutions used for
immunoblotting were as follows: Bcl-2 (sheep polyclonal
generated using GST-Bcl-2Δt; our laboratory; 1:10,000),
Bcl-XL (rabbit polyclonal generated against Bcl-XL; our
laboratory; 1:10,000), PARP (C-2-10, Biomol; 1:20,000),
caspases 7, 8 and 9 (ExAlpha Biologicals; 1:4,000). Actin
blots to ensure equivalent loading were developed with
clone C4 (ICN) diluted at 1:80,000. HRP linked second-
ary antibodies (Jackson Laboratories) donkey anti-rabbit
and donkey anti-mouse were used at dilutions of
1:10,000 and 1:80,000, respectively. To measure expres-
sion, the amount of exogenously expressed protein/
microgram total protein was determined by quantitative
immunoblotting of lysates from each MCF-7 clone. Quan-
tification was performed using a standard curve of defined
amounts of recombinant Bcl-2 or Bcl-XL from 3–6 blots,
using amounts of protein that were in the linear detection
range of enhanced chemiluminescence. The immunob-
lots were analyzed using the Kodak Image Station system
(440CF). A linear regression analysis was performed on
the net intensities of the standards and blots in which the
lines of best fit with R2 values of ≥ 0.95 were analyzed. To
identify appropriate clones of MCF-7 cells for further
study, more than thirty were screened. The concentration
of Bcl-2 or Bcl-XL in each MCF-7 clone used for further
experiments was assayed at least three times and showed
low inter-assay variability (<10%).
Measurement of cell death
During apoptosis PARP is cleaved into 24 and 89 kDa
fragments by caspase-7 in MCF-7 cells [31] and can be
degraded by lysosomal proteases to 62 and 55 kDa or 74
and 42 kDa fragments [32]. The C-2-10 monoclonal anti-
body recognizes full length and 89 kDa caspase cleaved
PARP, but does not recognize the cleavage products of
other proteases. Using this and other commercially avail-
able antibodies it is only possible to visualize the full
length protein, 89 and 24 kDa fragments. Therefore, to
assess PARP cleavage by caspase 7 as well as degradation
we measured the decrease in the amount of the full length
PARP. In each experiment the amount of actin in the sam-
ples was also recorded. If the actin blots indicated uneven
loading, transfer or development of the blots then the cor-
responding PARP data was not used. Doxorubicin
induced degradation of actin was detected only at drug
concentrations higher than 100 μM. Clonogenic survival
after doxorubicin exposure was performed as previously
described [33].
Results
Although generally regarded as mechanistically similar,
the effectiveness of Bcl-2 and Bcl-XL has not been com-
pared in a single defined cellular context. Such a compar-
ison is difficult because both proteins inhibit multiple
different pathways for apoptosis within a single cell line.
However, for a defined set of stimuli it is possible to com-BMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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pare Bcl-XL and Bcl-2 in the same context by measuring a
common event that occurs at or beyond a point of conver-
gence that is common to multiple cell death pathways.
Thus, the first step in comparing Bcl-2 and Bcl-XL is iden-
tification of suitable downstream events that can be
assayed.
Bcl-2 and Bcl-XL inhibit apoptosis induced by a variety of 
agents in MCF-7 cells
The drugs used to induce apoptosis are known to promote
apoptosis via different pathways: experiments with MCF-
7 and Rat-1 fibroblasts suggested that TG and ceramide
induce apoptosis at the endoplasmic reticulum upstream
of events at mitochondria [29,30]. The initial target site of
thapsigargin (TG) is the ER Ca++ pump SERCA2 [34]. C2
ceramide is a soluble version of a signalling molecule gen-
erated at the ER [35]. Mechanisms regulated at the endo-
plasmic reticulum are not expected to be involved in
doxorubicin induced apoptosis [30] as it inhibits topoi-
somerase II and generates free radicals [36]. TNFα acti-
vates caspase 8 to cleave Bid which in turn triggers Bax/
Bak to permeabilize mitochondria [37,38]. To determine
an appropriate way to compare apoptosis elicited by these
different mechanisms in MCF-7 cells, we examined cells
treated with the different agents for cleavage of caspases
and PARP as well as using Hoescht and Annexin V stain-
ing. Apoptosis was measured at a variety of concentra-
tions; however, in Figure 1 a single concentration and
time point are shown for each drug to facilitate visual
comparison. The dose and time were selected to maximize
the difference between control and Bcl-2/Bcl-XL express-
ing cells.
In vector transfected control cells all four agents induced
apoptosis, as assessed by the cleavage of PARP (Figure 1),
demonstrating that the effects on PARP occur downstream
of a point of convergence. In contrast, only TNFα led to
cleavage of caspase 8 (Figure 1). Furthermore, the absence
of caspase 8 cleavage with TG, ceramide and doxorubicin
establishes that caspase 8 cleavage cannot be used to com-
pare induction of apoptosis by TNFα with the other
agents.
MCF-7 cell lines expressing Bcl-XL and Bcl-2 were pro-
tected against apoptosis as judged by PARP cleavage
induced by TNFα, TG, ceramide and doxorubicin com-
pared to vector transfected (neo), control cells (Figure 1).
However, neither Bcl-2 nor Bcl-XL prevented TNFα
induced cleavage of caspase 8, indicating that both pro-
teins act downstream of activated caspase 8. Thus both
Bcl-2 and Bcl-XL inhibit downstream events elicited by
four agents that initiate cell death via different pathways.
To compare drugs that induce DNA damage (doxoru-
bicin) and those that act at the ER and do not cause direct
changes at the nucleus (TG) methods such as TUNEL
staining or chromatin condensation are not optimal. For
similar reasons, assessing cleavage of other caspases
proved impractical for comparing both a variety of drugs
and cells expressing Bcl-2 and Bcl-XL (data not shown).
The data in Figure 1 suggest that for MCF-7 cells, assaying
PARP cleavage can be used to determine whether
organelle targeted mutants of Bcl-2 and Bcl-XL show the
same pattern of protection against the mechanistically dis-
tinct apoptosis pathways activated by these four different
drugs. While not useful for all of the drugs studied here,
we found that chromatin condensation (assessed by Hoe-
scht staining) and externalization of phosphatidylserine
(assessed by Annexin V labelling) were useful to compare
some subsets of apoptotic agonists particularly in Rat-1
cells (see below).
Expression and subcellular localization of Bcl-2 and Bcl-XL 
mutants in MCF-7 cells
Bcl-2 and Bcl-XL inhibit multiple different pathways of
apoptosis. To examine the inhibition of multiple spatially
localized apoptosis pathways, we substituted the tail-
anchor from Bcl-XL with one specific for ER (cb5) or mito-
chondria (acta), as done previously with Bcl-2 [18]. Chi-
Prevention of apoptosis by Bcl-2 and Bcl-XL in MCF-7 cells Figure 1
Prevention of apoptosis by Bcl-2 and Bcl-XL in MCF-
7 cells. Cell lysates (20 μg of protein) of vector control 
(neo) and transfected MCF-7 cells expressing Bcl-2 or Bcl-XL 
(as indicated) were separated by SDS-PAGE, electroblotted 
and visualized using antibodies for PARP, actin or caspase 8 
as indicated. Untreated vector transfected cells (-) as a con-
trol for expression level in untreated cells. Expression of Bcl-
2 and Bcl-XL does not change the amount of PARP in 
untreated cells. Cells were exposed to 29 ng/ml TNFα and 
10 ng/ml cycloheximide (TNF) (30 h), 400 nM thapsigargin 
(TG) (60 h), 70 μMC2-ceramide (C2) (20 h), or 10 μM doxo-
rubicin (Dox) (24 h) as indicated above the lanes. The migra-
tion of the cleavage products of PARP and caspase 8 are 
indicated to the left of the bands by arrows. The migration 
positions of molecular weight markers are indicated in kDa 
to the left of the panels.BMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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maeras of Bcl-2 or Bcl-XL with the cb5 or acta tail anchors
are referred to as Bcl2-cb5 or BclX-cb5, and Bcl2-acta or
BclX-acta, respectively. Chimaeras of Bcl-2 and Bcl-XL
without a tail-anchor are referred to as Bcl2-Δt and BclX-
Δt, respectively. MCF-7 clones are referred to by the pro-
teins expressed. Quantitative western blotting was used to
select MCF-7 clones in which expression of the chimaeras
was equivalent to that of the wild-type proteins.
Bcl2-cb5 and Bcl2-acta are localized to ER and mitochon-
dria, respectively in several different cell lines [18-21,30].
However, localization of BclX-cb5 and BclX-acta has not
been examined previously. We therefore stained MCF-7
cells expressing targeted mutants with polyclonal antisera
to either Bcl-XL (Figure 2, panels A-D, I-J) or Bcl-2 (not
shown), and examined them by indirect immunofluores-
cence using confocal microscopy. Cells were co-stained
with antibodies recognizing either an inner mitochon-
drial membrane protein (Figure 2, 2G2, panels E-H) or an
ER protein (anti-calreticulin, Figure 2, panels K-L). As
expected, both BclX-acta and Bcl2-acta (data not shown)
are targeted to mitochondria in MCF-7 cells, as indicated
by the extensive co-localization observed with 2G2 (Fig-
ure 2, panels A, E), but not with the endoplasmic reticu-
lum chaperone calreticulin (Figure 2, panels I, K). The
distribution of wild-type Bcl-XL co-localized with 2G2
indicating that in MCF-7 cells the Bcl-XL expressed exoge-
nously is located primarily at mitochondria (Figure 2,
panels C, G). Wild-type Bcl-2 had a similar distribution in
MCF-7 cells (data not shown). By contrast, BclX-cb5 (Fig-
ure 2, panels B, F) and Bcl2-cb5 (data not shown) do not
localize to mitochondria, but instead exhibited a net-like
cytoplasmic staining that co-localized with calreticulin
(Figure 2 panels J, L). Bcl-XL without a tail-anchor (BclX-
Δt) was distributed diffusely throughout the cytoplasm
and in the nucleus without accumulating at mitochondria
(Figure 2, panels D, H). The significant amount of nuclear
staining seen with this construct suggests that the Bcl-XL
tail-anchor prevents nuclear import, perhaps because it is
essential for the formation of Bcl-XL dimers [39] that
unlike the monomer, are too large to diffuse through the
nuclear pore. The localization of Bcl2-acta, Bcl2-cb5, BclX-
acta, BclX-cb5 and BclX-Δtm detected by immunofluores-
cence was also confirmed by subcellular fractionation of
cell lysates (data not shown).
In MCF-7 cells Bcl-2 and Bcl-XL regulate organelle specific 
pathways of apoptosis differently
Using MCF-7 clones expressing Bcl-2, Bcl-XL or targeted
mutants, we assessed the differences in inhibition of
apoptosis induced by the agents characterized above. The
dose and time were selected such that most of the PARP in
the vector expressing control cells is cleaved to the charac-
teristic 89 kDa fragment (ΔPARP). This dose was chosen
because the closer the treatment is to the limit of inhibi-
tion, the more sensitive the assay is to differences between
mutants. As expected, in cells expressing Bcl-2 or Bcl2-acta
there was much less PARP cleavage. However, Bcl2-cb5 is
largely ineffective at preventing doxorubicin induced
cleavage of PARP. To our surprise, BclX-cb5 functioned
differently than Bcl2-cb5 and prevented PARP cleavage as
effectively as Bcl-XL and BclX-acta. Although BclX-Δtm
was less effective than Bcl-XL it was much more effective
at preventing PARP cleavage than Bcl2-cb5. Similarly,
there was little to no inhibition of TNFα induced PARP
cleavage by Bcl2-cb5 (Figure 3). In contrast, BclX-cb5 was
relatively effective at inhibiting apoptosis induced by
TNFα. This suggests that there is a fundamental difference
in the function of Bcl-2 and Bcl-XL at the endoplasmic
reticulum. Although based on this data alone it is formally
possible that Bcl2-cb5 is misfolded and non-functional
the fact that Bcl2-cb5 prevents apoptosis induced by either
ceramide or TG demonstrated that Bcl2-cb5 is a func-
tional protein (Figure 3).
When apoptosis was elicited by ceramide or TG, both
Bcl2-cb5 and BclX-cb5 were as, or more, effective than the
respective wild type proteins and mitochondrial targeted
mutants (Figure 3). Ceramide treatment that resulted in
cleavage of all of the PARP in control cells was not inhib-
ited very well by any of the proteins, so for this agonist a
concentration was used that resulted in cleavage of about
half the PARP in the control cells (neo). For TG treated
control cells, all the PARP was cleaved and/or degraded,
and the amount of PARP cleavage in Bcl-2, BclX-acta and
BclX-Δt cells indicates that this dose and time of TG treat-
ment is close to the maximum inhibited by these proteins.
As Bcl-2 expression is approximately four times higher
than Bcl-XL and protection from apoptosis is similar but
incomplete, Bcl-XL is at least four times as efficient as Bcl-
2 at inhibiting cell death due to TG.
The striking difference in activity of Bcl2-cb5 and BclX-cb5
was also evident when TNFα induced apoptosis was
assessed qualitatively by staining cells with Hoescht dye
(to visualize chromatin condensation) and Annexin V (to
visualize externalization of phosphatidylserine at the
plasma membrane) (Figure 3B). Staining cannot be used
to assess cells treated with doxorubicin as the drug is
highly fluorescent. Moreover in MCF-7 cells treated with
TNFα, quantification is difficult because the period and
extent of chromatin condensation is small and it is fol-
lowed by extensive chromatin degradation resulting in
loss of staining. Nevertheless, it is qualitatively obvious
from the images that BclX-cb5 inhibits apoptosis induced
by TNFα while Bcl2-cb5 does not.
Thus, targeting Bcl-2 and Bcl-XL to endoplasmic reticulum
has drastically different effects on function, depending on
the agent used to elicit apoptosis. In contrast, mitochon-BMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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drial localized Bcl2-acta and BclX-acta were very effective
against all four agents, demonstrating that the mitochon-
dria are a point of convergence in the apoptosis pathways
induced by a wide variety of drugs (Figure 3A).
Surprisingly, BclX-Δt was considerably more effective than
vector control in preventing apoptosis due to all three
agents (Figure 3A). This suggests that at least a part of the
protective ability of Bcl-XL does not require membrane
binding mediated by a tail-anchor. A significant propor-
tion of BclX-Δt measured by quantitative immunoblotting
was located in the nucleus by immunofluorescence micro-
scopy (Figure 2, panels D and H) where the relevant bind-
ing partners that regulate apoptosis are probably not
accessible. Therefore, our data may underestimate the
intrinsic activity of BclX-Δt in prevention of apoptosis. We
Subcellular localization of Bcl-XL, BclX-acta, BclX-cb5 and BclX-Δt Figure 2
Subcellular localization of Bcl-XL, BclX-acta, BclX-cb5 and BclX-Δt. Panels A-D, cells stained with an affinity purified 
polyclonal antiserum to full length Bcl-XL, and visualized with a fluorescein-conjugated donkey anti-rabbit antibody. Panels E-
H, the corresponding images of the same cells in A-D stained with a monoclonal antibody to a mitochondrial inner membrane 
protein (2G2) and visualized with rhodamine-conjugated goat anti-mouse antibody. Panels I-J, cells stained with an affinity puri-
fied polyclonal antiserum to full length Bcl-XL conjugated directly to fluorescein and K-L, the corresponding images of the 
same cells stained with a polyclonal antibody to calreticulin. The protein expressed in each cell line is indicated to the left of the 
panels. The width of each image is 50 microns.BMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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were not able to systematically examine cells expressing
Bcl2-Δt to determine the requirement for membrane
insertion of this protein because immunoblotting of cells
expressing Bcl2-Δt indicated more than half of the mole-
cules were modified as detected by decreased mobility on
SDS-PAGE (data not shown). Because this modification
has an unknown effect on function, Bcl2-Δt was not exam-
ined further.
In rat fibroblasts Bcl-2 and Bcl-XL regulate organelle 
specific pathways of apoptosis differently
To determine if the difference between Bcl2-cb5 and BclX-
cb5 is specific to MCF-7 cells we expressed Bcl-2, Bcl-XL,
Bcl2-cb5 and BclX-cb5 in rat fibroblasts. We have shown
previously that Bcl2-cb5 prevents apoptosis induced by
agents that target the ER but does not inhibit apoptosis
initiated at mitochondria in Rat-1 cells [29,30]. Based on
Prevention of apoptosis in MCF-7 cells by Bcl-2 and Bcl-XL and by mutants with restricted subcellular localization Figure 3
Prevention of apoptosis in MCF-7 cells by Bcl-2 and Bcl-XL and by mutants with restricted subcellular localiza-
tion. A) Cell lysates containing 20 μg of protein from vector control (neo) or transfected MCF-7 cells expressing wild type 
proteins or proteins with restricted subcellular localization [ER (Bcl2-cb5, BclX-cb5), mitochondria (Bcl2-acta, BclX-acta) or 
nucleo-cytoplasm (BclX-Δt)] as indicated above the lanes were immunoblotted for PARP and actin. Cells were exposed to 
doxorubicin (Dox), TNFα and cycloheximide (TNF), ceramide (C2), or thapsigargin (TG) as in Figure 1. Untreated vector 
transfected cells (-). Expression of Bcl-2, Bcl-XL and the targeted mutants does not change the amount of PARP in untreated 
cells. The migration position of the 89 kDa caspase cleaved PARP fragment is indicated as ΔPARP. B) MCF-7 cells either 
untreated and transfected with the control plasmid (Neo -) or stably expressing the indicated protein and treated with TNFα 
and cycloheximide were stained with Hoescht 33342 (blue) or Annexin V coupled to Alexa Fluor594 (red) and visualized by 
epifluorescence microscopy. The width of each image is ~660 μm.BMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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our earlier results we compared cell death induced by
etoposide and low serum. Because we are comparing only
these two agents it is also possible to use other assays in
addition to PARP cleavage to measure the induction of
apoptosis in the Rat-1 cell clones. As expected, control
cells transfected with the empty vector (neo) are very sen-
sitive to both etoposide and low serum (Figure 4), as a
result PARP is cleaved, the nuclei condense as shown by
Hoescht staining, and lipid asymmetry at the plasma
membrane is lost resulting in externalization of phos-
phatidylserine (detected by labelling cells with Annexin
V). In Rat-1 cells nuclear condensation is dramatic and
quantitative thus, the results can be quantified from
micrographs (Figure 4C). Bcl-2, Bcl-XL and BclX-cb5 all
inhibited, but did not completely eliminate, nuclear con-
densation. Bcl2-cb5 was not effective at inhibiting etopo-
side induced nuclear condensation. Similarly, the fraction
of cells that are annexin V positive is similar for the con-
trols and Bcl2-cb5 expressing cells, whereas it is much
reduced for cells expressing Bcl-2, Bcl-XL and importantly
BclX-cb5 (Figure 4B–C). The most likely explanation for
this result is that similar to MCF-7 cells, ER localized Bcl2-
cb5 is unable to inhibit etoposide induced apoptosis even
though it can be inhibited by BclX-cb5 proteins located at
the same organelle. To demonstrate that this is a bona fide
difference in activity between the two proteins and not a
result of Bcl2-cb5 being inactive in rat fibroblasts, apopto-
sis was also induced in the cells by growth in low serum.
Under these treatment conditions both Bcl2-cb5 and
BclX-cb5 prevent apoptosis as well as the wild type pro-
teins (Figure 4). Although all of the Bcl-2 family proteins
prevent nuclear condensation as measured by Hoescht
staining, none of the proteins prevented shrinkage of the
nucleus (Figure 4) that occurs when cells are grown in low
serum. While the difference in efficacy of BclX-cb5 and
Bcl2-cb5 is obvious for these clones, these cells express
unknown quantities of endogenous Bcl-2 and Bcl-XL
complicating quantitative assessment.
Bcl-XL is ten times more effective than Bcl-2 at preventing 
apoptosis in MCF-7 cells
It is clear from the results above that Bcl-2 and Bcl-XL
inhibit many different forms of apoptosis. Previous
reports suggest that expression levels of Bcl-2 or Bcl-XL in
cells determine the extent of inhibition [40]. While there
are some indications in the data above that Bcl-XL is more
efficient than Bcl-2 at inhibiting apoptosis, quantitative
comparison of Bcl-2 and Bcl-XL requires selection of
transfected clones stably expressing known amounts of
protein that does not vary with multiple passages, unlike
what can be observed with pools of transfectants used in
previous studies. As expected for stable clones of cell lines,
all the cells expressed the transfected protein after expan-
sion, as assessed by immunofluorescence (data not
shown). Because our preliminary experiments demon-
strated that Bcl-XL was more effective than Bcl-2 at pre-
venting apoptosis, transfected cell lines grown in estrogen
depleted medium (to decrease endogenous Bcl-2) were
identified that consistently expressed roughly equipotent
amounts of either Bcl-2 or Bcl-XL (range 1.2 to 4.5 ng /μg
protein or 0.3 to 0.8 ng /μg protein, respectively and sum-
marized in Table 1).
To accurately measure Bcl-2 and Bcl-XL in the cells we
used quantitative immunoblotting. Standard curves on
the same blots as the cell lysates demonstrated that detec-
tion of protein concentration was linear throughout the
range needed for detection of the proteins. It was also
essential to screen cells for equivalent expression after
growth in estrogen depleted medium as a number of the
clones exhibited striking changes in the amount of protein
expressed in response to estrogen (data not shown). This
is presumably a result of the site of integration of the exog-
enous DNA in the genome of the MCF-7 cells. Changes in
the amount of the anti-apoptotic proteins during apopto-
sis were measured for all of the proteins, and with the
exception of Bcl2-acta after doxorubicin treatment, paral-
leled each other and did not correlate with functional
effects (see below). Furthermore, we extensively tested
two separate clones that expressed closely matched levels
of Bcl-2 (3.6 and 4.5 ng Bcl-2/μg protein) and performed
partial comparisons for independent duplicates of the
other cell lines. In all cases we obtained similar results,
indicating that observed differences between the cell lines
used for quantitative comparisons below were not due to
clonal variation, but were due to the expression of the
exogenous proteins (data not shown). Thus, we conclude
that these clones can be used to compare quantitatively
the effects of Bcl-2, Bcl-XL and the targeted mutants.
The assays chosen to measure apoptosis were cleavage of
PARP and clonal survival. As shown above, PARP cleavage
occurs downstream of convergence of the different apop-
tosis pathways and there is no feedback activation of cas-
pase 8 after treatment of MCF7 cells with drugs (Figure 1).
This lack of feedback amplification, likely due to lack of
caspase 3, simplifies the interpretation of PARP cleavage
data making it more useful for quantitative comparisons.
Finally, PARP cleavage assayed by quantitative immunob-
lotting appears to have a larger dynamic range than either
Hoescht staining or Annexin V labelling (data not
shown).
A further qualitative difference between inhibition of
apoptosis by Bcl-2 and Bcl-XL was evident at doses of dox-
orubicin that were effective at overcoming Bcl-2/Bcl-XL
resistance. At these concentrations, cleavage of PARP at
the site that generates the 89 kDa product characteristic of
cleavage by Caspase 7 was evident in Bcl-2 expressing
lines (Figure 5, left panels, arrow). By contrast, cleavage ofBMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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Prevention of apoptosis in Rat-1 cells by Bcl-2 and Bcl-XL and by ER localized mutants Figure 4
Prevention of apoptosis in Rat-1 cells by Bcl-2 and Bcl-XL and by ER localized mutants. A) Cell lysates containing 
20 μg of protein from vector control (neo) or transfected Rat-1 cells expressing wild type proteins or ER localized mutants 
(Bcl2-cb5, BclX-cb5) as indicated above the lanes were immunoblotted for PARP and actin. Cells were exposed to etoposide 
or low serum. Untreated vector transfected cells (-). The migration position of the 89 kDa caspase cleaved PARP fragment is 
indicated as ΔPARP. B) Rat-1 cells transfected with the control plasmid (Neo -) or stably expressing the indicated protein and 
treated with TNFα and cycloheximide were stained with Hoescht 33342 or Annexin V coupled to Alexa Fluor594 (as indicated 
above the panels) and visualized by epifluorescence microscopy. A few normal nuclei are indicated by open arrowheads while 
examples of condensed nuclei are indicated by solid arrowheads. The width of each image is ~660 μm. C) Quantification of the 
results from experiments similar to those shown in B). Each determination represents 450–600 cells analyzed converted to % 
positive by dividing by the total number of Hoescht stained cells, independent of whether chromatin condensation was 
observed.BMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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PARP at this site was minimal in cells expressing Bcl-XL
even at high doses (with the exception of cells expressing
BclX-Δt, Figure 3). Instead, the total amount of PARP was
decreased, indicating the degradation products in these
cells were not recognized by the antibody (Figure 5, left
panels). As many other proteases, including lysosomal
proteases, are active during apoptosis [41], this suggests
that Bcl-XL expression almost completely inhibits activa-
tion of effector caspases but not other proteases that medi-
ate doxorubicin induced cell death. Since the 89 kDa
Quantitative determination of PARP cleavage and degradation in MCF-7 cells following induction of apoptosis by treatment  with doxorubicin Figure 5
Quantitative determination of PARP cleavage and degradation in MCF-7 cells following induction of apoptosis 
by treatment with doxorubicin. The left panel shows the results of vector transfected (Neo) (top), Bcl-2 (middle) and Bcl-
XL (bottom) expressing MCF-7 cells treated for 48 hours with increasing doses of doxorubicin as indicated, and cell lysates 
immunoblotted for PARP. The migration position of the 89 kDa PARP fragment diagnostic of caspase cleavage is indicated to 
the left of the blots (arrow). The antibody used for immunoblotting does not recognize cleavage products generated by other 
proteases activated during apoptosis. Therefore, both PARP cleavage and degradation were combined into a single apoptosis 
index (right panel, top) determined by measuring the band intensities for the116 kDa full length PARP in untreated cells (green 
box, 0), and in cells treated with doxorubicin (e.g. blue box) for the dose indicated above the lanes, on a Kodak image station. 
Actin blots were used to demonstrate equal protein loading in each lane (Figure 6). This index is plotted versus dose of doxo-
rubicin for vector transfected cells (neo), and for cells expressing 3.6 ng Bcl-2 and 0.9 ng Bcl-XL per μg of total cell protein, 
respectively (right panel, bottom). EC50 values determined from the resulting dose response curves are indicated with coloured 
upward arrows.
Table 1: Expression of Bcl-2, Bcl-XL and mutant proteins in MCF-7 cells.
Cell Clone Number of Independent 
Experiments
Expression of Bcl-2 or Bcl-
XL proteins (ng/μg total 
protein) no drug
Expression of Bcl-2 or Bcl-
XL proteins (ng/μg total 
protein) at the EC50 dose 
of doxorubicin
EC 50 doxorubicin (μM)
 Inhibition of PARP 
degradation.
Neo 5 n.d. n.d. 1.9 ± 0
Bcl-2 (#2) 6 4.5 ± 1.0 2.5 ± 0.1 22.8 ± 3.3
Bcl-2 (#5) 7 3.6 ± 0.7 1.6 ± 0.1 30.6 ± 1.0
Bcl2-acta (#24) 7 1.2 ± 0.3 0.2 ± 0.02 13.2 ± 1.7
Bcl2-cb5 (#18) 5 1.5 ± 0.4 1.3 ± 0.02 2.3 ± 0.1
Bcl-XL (#42) 6 0.8 ± 0.2 0.7 ± 0.05 85.4 ± 0.6
BclX-Δt (#1) 5 0.6 ± 0.1 0.5 ± 0.01 8.7 ± 1.7
BclX-acta (#6) 4 0.3 ± 0.1 0.2 ± 0.02 97.8 ± 1.5
BclX-cb5 (#24) 5 0.6 ± 0.1 0.6 ± 0.1 32.3 ± 1.8BMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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product was eventually also degraded in Bcl-2 expressing
cells, these additional proteases are active in clones
expressing either protein. Degradation of PARP is still a
specific indicator of programmed cell death and not a
result of a general loss of cell protein as shown by blotting
for actin (see below).
Loss of full length PARP is the most appropriate measure
of cell death since both cleavage and degradation are
accounted for (Figure 5, right panel). Using this metric as
an apoptosis index we constructed doxorubicin dose
response curves for control cells (neo) and cell clones
expressing Bcl-2, Bcl2-cb5 or Bcl2-acta (Figure 6A) and for
Bcl-XL, BclX-cb5, BclX-acta or BclX-Δt (Figure 6B) from
immunoblots. This data confirms that for a wide range of
drug concentrations the differences in inhibition of apop-
tosis noted with a single concentration of doxorubicin
(Figure 3A) are preserved.
Comparison of the dose response curve for Bcl2-cb5 with
the control demonstrates a complete lack of activity for
Bcl2-cb5 at every concentration of doxorubicin tested
(Figure 6A). To compare different cell lines directly, dose
response curves were used to obtain an EC50, defined as
the drug concentration that caused the disappearance
and/or cleavage of half of the pre-treatment PARP (Figure
5 arrows, left panel).
The absolute amount of the anti-apoptotic proteins in
each cell line and the apoptosis index were used to derive
a measure of functional activity, defined as the EC50 of
doxorubicin in μM (Figure 6A) divided by molar amount
of anti-apoptotic protein expressed per μg of cell protein.
Calculation of functional activity in this way permits nor-
malization of the data for differences in the expression
level of the exogenous proteins. However, such normali-
zation is complicated by the fact that the amount of pro-
tein expressed is altered by drug treatment. Therefore, to
determine the true extent of variation within the data and
provide estimates of the relative efficacy of the different
proteins, functional activities were calculated using both
the amount of exogenous protein expressed prior to drug
treatment and the amount of exogenous protein present
at the time of assay at the EC50 for doxorubicin for each
clone. The results of both calculations were compared by
normalizing to Bcl-2 clone #2 which was arbitrarily set to
1). As a control to show the amount of variation for Bcl-2
we examined clone #5 as part of this analysis. Using this
method to determine activity, it is clear that on a molar
basis Bcl-XL prevented PARP degradation at a concentra-
tion of doxorubicin that is at least ten times higher than
was inhibited by Bcl-2 (Figure 6C). Part of this increased
efficacy may be due to the fact that the Bcl-XL associated
with the ER is effective, whereas Bcl-2 is not able to pre-
vent doxorubicin induced apoptosis from the ER. How-
ever, even when targeted to mitochondria where both
proteins are active against doxorubicin induced apoptosis,
Bcl-XL is much more efficacious than Bcl-2 (Figure 6C).
The shape of the dose response curve for Bcl2-acta differs
from that of both wt Bcl-2, and BclX-acta (Figure 6A and
6B). Unlike the other mutants, addition of 5–20 μM dox-
orubicin strongly reduced the amount of Bcl2-acta as
determined by quantitative immunoblotting. Because the
same effect was seen in several different independently
derived cell clones including those expressing more or less
Bcl2-acta than the clone used here (data not shown) we
presume that Bcl2-acta is more susceptible to a protease
that is activated by low doses of doxorubicin. It is unclear
whether this proteolytic activity is related to the organelle
specific degradation of Bcl-2 that has been reported in
other cell types after exposure to cytotoxic agents [42]. We
did not observe any pro-apoptotic caspase cleavage prod-
ucts of Bcl-2 [43] or Bcl-XL [44] that have been described
in other systems, possibly due lack of caspase 3 in MCF-7
cells.
Dose response curves were also used to assess the require-
ment of membrane binding for Bcl-XL activity. In many
cell types a substantial fraction of Bcl-XL is cytoplasmic
(e.g. 17), or as in these MCF-7 cells, peripherally bound to
membranes when cells are not stressed (Zhu, Leber and
Andrews, unpublished data). BclX-Δt remains nucleo-
cytoplasmic during apoptosis but when assayed with dox-
orubicin it has higher functional activity than Bcl-2 (Fig-
ure 6C). Nevertheless, this activity is much less than that
of Bcl-XL. BclXL-cb5 is also membrane bound and is sub-
stantially more active than BclXL-Δt. However, we cannot
be sure how much of the activity of the latter is under-esti-
mated by mis-targeting to putatively inactive sites in
nucleus, as noted above (Figure 3, panels D and H). Thus,
a significant amount of the activity of BclX-cb5 may not be
due to specific location at the ER and interaction with res-
ident membrane proteins at that organelle, but rather by
sequestering and inactivating cytoplasmic pro-apoptotic
proteins. A similar mechanism has been proposed for the
activity of Bcl2-cb5 in preventing apoptosis by sequester-
ing Bad [21].
As an independent and more clinically relevant means of
comparing the effects of Bcl-2 and Bcl-XL on apoptosis
[45], we measured clonal survival by re-plating efficiency
of MCF7 cells exposed to 5μM doxorubicin for 1 hour
[33]. This assay allows us to determine if the different
effects on PARP cleavage and Annexin V labelling translate
to the biologically and clinically relevant outcome of cell
survival [37]. Consistent with results observed with meas-
urement of residual PARP after exposure to doxorubicin,
Bcl-XL was much more effective than Bcl-2 in promoting
cell survival (Figure 7A). Furthermore, when corrected forBMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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The functional activity of Bcl-XL in preventing doxorubicin induced apoptosis is about ten times greater than that of Bcl-2 Figure 6
The functional activity of Bcl-XL in preventing doxorubicin induced apoptosis is about ten times greater than 
that of Bcl-2. Cell lines expressing A) Bcl-2, Bcl2-cb5 or Bcl2-acta and B) Bcl-XL, BclX-cb5, BclX-acta or BclX-Δt were 
treated with the specified dose of doxorubicin, and plotted against the apoptosis index (measured as in Figure 5). The data rep-
resenting the dose response curves for vector transfected control cells (neo), Bcl-2 or Bcl-XL expressing cells shown in Figure 
5 is duplicated here for comparison. The relative intensity recorded for actin blots prepared from the same samples are shown 
to the right and indicate that equivalent amounts of protein were analyzed for all samples. Bars indicate standard error of the 
mean, n ≥ 4. C) The EC50 values in μM doxorubicin for Bcl-2, Bcl-XL and mutants located at the ER (Bcl2-cb5, BclX-cb5), mito-
chondria (Bcl2-acta, BclX-acta) or cytoplasm (BclX-Δt) as determined from the graphs shown in A) and B). To correct for 
expression of the individual proteins these values were divided by the concentration of anti-apoptotic protein (expressed as 
nMol/mg total cell protein normalized to Bcl-2 #2) in each cell line. Grey bars – based on expression levels prior to drug treat-
ment. Black bars – based on expression levels after drug treatment at the EC50.BMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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expression level, the targeted mutants of Bcl-XL exhibited
a similar order of efficacy, with BclX-acta > BclX-cb5 >
BclX-Δt, although Bcl-XL was more effective than BclX-
acta (Figure 7B). To our surprise Bcl2-cb5 promoted
clonal survival after exposure of cells to 5 μM Doxorubicin
for one hour even though it was unable to prevent cleav-
age of PARP after exposure to the same amount of drug for
24 hours. Therefore, the replating assay detected residual
activity of Bcl2-cb5 not detectable with the PARP cleavage
assay. However, the rest of the clonal survival data paral-
lels that observed for cleavage of PARP.
Discussion
Our results indicate that Bcl-XL and Bcl-2 are not func-
tionally interchangeable. The organelle targeted mutants
demonstrate that in both MCF-7 and Rat-1 cells Bcl-2 and
Bcl-XL are qualitatively different: BclX-cb5 prevents apop-
tosis due to TNFα, doxorubicin (Figures 3, 6) and etopo-
side (Figure 4), whereas Bcl2-cb5 is ineffective. This
extends our concept of organelle specific pathways of
apoptosis by demonstrating that within a single cell type, a
stressful stimulus elicits events at the ER differentially
inhibited by Bcl-XL compared to Bcl-2. As apoptosis can
be inhibited at either ER or mitochondria, this implies
that changes at both organelles are necessary for apoptosis
[22]. The most likely reason that when corrected for
expression targeted mutants appear more effective than
wild-type proteins is that at equal levels of expression
there is twice as much protein at a single organelle. We
speculate that for this reason the targeted mutants more
efficiently inhibit one essential pathway whereas the wild-
type proteins partially inhibit two pathways (Figure 6C).
The difference in efficacy we observed for BclX-cb5 and
BclX-acta suggests that inhibition of apoptosis by seques-
tration of cytoplasmic effectors (the presumed mecha-
nism of action for BclX-cb5) may be an activity
independent from another function of the Bcl-XL that
integrates into mitochondria. It is likely that this latter
activity involves inhibiting oligomerization of Bax and
Bak [51].
We also noted a quantitative difference between Bcl-2 and
Bcl-XL in preventing doxorubicin induced apoptosis: Bcl-
XL is about ten times more efficient than Bcl-2. This
marked difference may explain the different prognostic
values of Bcl-2 compared to Bcl-XL expression in human
breast cancer samples independent of the presence of the
estrogen receptor.
Our experiments demonstrate that small differences in the
amount of anti-apoptosis proteins lead to large differ-
ences in cell survival. This is especially notable with Bcl-
XL, and has important implications for clinical correlative
studies where the ability to distinguish between different
levels of expression of Bcl-XL and other anti-apoptotic
proteins by immunohistochemistry is limited, and in
which intercellular variability in the expression of Bcl-XL
is within this critical range. While important clinical cor-
relations have been found in many studies, our results
suggest that biologically relevant variation may not always
be detectable by these assays.
Because anti-apoptotic Bcl-2 family proteins participate in
complex pathways with many components, the qualita-
tive and quantitative differences in function for Bcl-2 and
Bcl-XL may be mediated by altered binding affinity to
The functional activity of Bcl-XL is more than ten times  greater than Bcl-2 in increasing clonal survival after exposure  to doxorubicin Figure 7
The functional activity of Bcl-XL is more than ten 
times greater than Bcl-2 in increasing clonal survival 
after exposure to doxorubicin. A) Cells expressing Bcl-2 
or Bcl-XL, as indicated, were exposed to 5 μM doxorubicin 
in estrogen free medium for 1 hour, then replated in drug 
free, estrogen replete medium and allowed to grow for 14 
days. Surviving colonies were visualized by staining with crys-
tal violet. B) The number of surviving clones was counted and 
the results expressed as the number of surviving clones cor-
rected for expression level of the respective protein for each 
cell clone. The data shown on a logarithmic scale is from one 
experiment performed in triplicate and is representative of 
three independent experiments. Bars indicate standard error 
of the mean.BMC Cancer 2006, 6:213 http://www.biomedcentral.com/1471-2407/6/213
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other proteins that affect apoptosis (including but not
limited to pro-apoptotic Bcl-2 family members, as has
been recently reported, 46). Membrane binding is also
important for many aspects of the function of these pro-
teins, including the binding of pro-apoptotic Bcl-2 family
proteins [47,48]. Therefore, the mechanisms and conse-
quences of membrane integration of different anti-apop-
totic proteins [39,46,49-51] is an important component
in elucidating the differences between family members.
Our results suggest that efficient sequestration of pro-
apoptotic proteins depends on both the intrinsic prefer-
ences of Bcl-2 and Bcl-XL for particular targets as well as
which organelle membrane the proteins are associated
with. The most important general implication of our find-
ings however, is that the exact mechanism of action in pre-
venting apoptosis must be determined independently and
specifically for each Bcl-2 family protein.
Conclusion
When examined in the same cellular context, Bcl-2 and
Bcl-XL differ substantially in the potency with which they
inhibit apoptosis, mediated in part by differences in the
inhibition of specific subcellular pathways.
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